SubHero Banner
Text

Fiasp® (insulin aspart) – Expanded indication

December 19, 2019 - The FDA approved Novo Nordisk’s Fiasp (insulin aspart), to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Download PDF